Search Results

Freenome, a biotechnology company developing blood tests for early cancer detection, announced the addition of $254 million from new and existing investors.

Freenome announced Thursday a fundraising round of more than a quarter of a billion dollars, led by Roche, to advance its blood-based cancer tests as pivotal readouts approach.

Walgreens and Freenome today announced a multi-year relationship to advance clinical studies of Freenome’s blood-based tests for the early detection of cancer. Walgreens will combine its national footprint, patient insights, compliant recruitment technology and local infrastructure to engage diverse patient populations in Freenome’s multi-cancer research program.

Freenome, a biotechnology company pioneering an early cancer detection platform, today announced topline results from PREEMPT CRC, a prospective, registrational clinical study to validate its blood-based test for the early detection of colorectal cancer (CRC) among average-risk adults.

Freenome today announced the initiation of its PROACT LUNG study and provided an update on its lung cancer research, including the ongoing Vallania study.

Freenome, a privately held biotech company announced that Renown Health has joined as a partner for the Sanderson Study, Freenome’s study of its multiomics platform, in combination with real-world data to detect multiple cancers.

Freenome announced it has acquired Oncimmune Ltd, a UK-based global immunodiagnostics developer with a commercialized CE-IVD marked EarlyCDT Lung blood test, autoantibody platform and research and development pipeline of 7+ cancer detection signatures.

Freenome, a privately held biotech company, announced that the Institute for Population and Precision Health at the University of Chicago has joined as a study partner for its Vallania Study.